-
Clinical Trials & Development1 day agoBrazil’s VigiMed database reveals radiopharmaceutical safety reporting patterns
A retrospective analysis of Brazil's VigiMed database identified 191 radiopharmaceutical drug entries in 126 adverse event reports, with Xofigo and Pluvicto accounting for most entries and...
-
Clinical Trials & Development1 day agoArtiva Axes 94% of Workforce, Weighs Strategic Alternatives After Two Patients in Phase IIa Trial Die
In announcing the layoffs and strategic alternatives review, Artiva disclosed that two patients in the trial who underwent the study treatment died in Grade 5 safety...
-
Clinical Trials & Development2 days agoVitamin Derivative Pantethine Alleviates Psoriasis Symptoms in Small Human Trial
Researchers found that the vitamin B5 derivative pantethine prevented the development of psoriasis in mice, and in a small-scale trial in human psoriasis patients administering pantethine...
-
Clinical Trials & Development2 days agoEMSO 2026: Incyte a ‘firm contender’ in G12D pancreatic cancer race as early candidate shines
In a Phase 1 study, treatment with Incyte's KRAS G12D inhibitor in combination with standard-of-care chemotherapy elicited an 89% confirmed objective response rate in patients with...
-
Clinical Trials & Development2 days agoNovartis faces $1.9B hit from Avidity fail but maintains confidence in $12B buy
Novartis remains "very happy" with its $12 billion acquisition of Avidity Biosciences, despite a Phase 3 disappointment for the antibody-oligonucleotide conjugate del-desiran.
-
Clinical Trials & Development2 days agoOpinion: Cancer vaccines are finally here. How do we get them to patients?
“If we want cancer vaccines to reach patients faster than BRCA testing did, there are several challenges to address now,” write Karen E. Knudsen and Othman...
-
Clinical Trials & Development2 days agoSacituzumab Tirumotecan (Sac-TMT) Reduced the Risk of Death by 32% and the Risk of Disease Progression or Death by 41% Compared to Chemotherapy in Certain Patients With Advanced or Recurrent Endometrial Cancer
RAHWAY, N.J.--(BUSINESS WIRE) October 26, 2026 -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of...
Genmab’s cancer bispecific delivers early survival win in ‘exceedingly positive’ Phase 3 readout
Genmab’s cancer bispecific delivers early OS win in ‘exceedingly positive’ Phase 3 readout
STAT+: HHS moves to allow compounding of some unapproved peptides
Novartis buys Synnovation’s PI3Kα inhibitors for $3 billion
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
